KAT7 and acute lymphoblastic leukemia: In contrast, WM-3835 did not affect the viability of normal human PBMC as well as HBO1 knockdown B-ALL cells (Fig. 8C, D), which suggested that WM-3835 was safe and acted against B-ALL by targeting HBO1.